<DOC>
	<DOC>NCT00863590</DOC>
	<brief_summary>This study assessed the safety, tolerability, and pharmacokinetics of single-dose odanacatib (MK0822) with and without food.</brief_summary>
	<brief_title>A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Subject is in good health Subject is a male between the ages of 18 and 45 years or (for Part I only) a female 60 years or younger Female subject is postmenopausal Subject is within 20% of ideal body weight Subject is a nonsmoker Subject has multiple or severe allergies to food or medications Subject has a history of metabolic bone disease, kidney/bladder stones, or treatment with bisphosphonates Subject has any infections, including HIV Subject consumes excessive amounts of caffeine or alcohol Subject has donated blood or taken another investigational drug in the last month Subject has a history of any illness that may confound the results of the study or pose additional risk in administering the study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>